NIKITA
Peakpitavastatin sodium
NDAORALTABLET
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NIKITA (pitavastatin sodium) is 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase, the enzyme that catalyzes the conversion of hmg-coa to mevalonate, a rate-limiting step in the biosynthetic pathway for cholesterol. First approved in 2017.
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NIKITA (pitavastatin sodium) is an oral HMG-CoA reductase inhibitor statin approved in 2017 for cholesterol management. It works by inhibiting the rate-limiting enzyme in cholesterol biosynthesis, increasing LDL receptor expression and hepatic uptake of LDL, thereby reducing plasma total cholesterol and VLDL levels. The drug is indicated for patients requiring lipid-lowering therapy to reduce cardiovascular risk.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30); team likely focused on market penetration and retention rather than expansion.
Mechanism of Action
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a rate-limiting step in the biosynthetic pathway for cholesterol. As a result, the expression of LDL-receptors followed by the uptake of LDL from blood to liver is…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NIKITA careers are concentrated in commercial and field-based roles given peak-stage lifecycle and market saturation. Positions focus on defending market share against generics and maintaining formulary access rather than launching or expanding indications.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.